| 6744- | DSF, | Disulfiram modulated ROS-MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | T47D |
| 6740- | DSF, | Targeting the NPL4 Adaptor of p97/VCP Segregase by Disulfiram as an Emerging Cancer Vulnerability Evokes Replication Stress and DNA Damage while Silencing the ATR Pathway |
| - | in-vitro, | Var, | NA |
| 6739- | DSF, | Disulfiram's anti-cancer activity reflects targeting NPL4, not inhibition of aldehyde dehydrogenase |
| - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | A549 |
| 4913- | DSF, | Anticancer effects of disulfiram: a systematic review of in vitro, animal, and human studies |
| - | Review, | Var, | NA |
| 4914- | DSF, | immuno, | Disulfiram and cancer immunotherapy: Advanced nano-delivery systems and potential therapeutic strategies |
| - | Review, | Var, | NA |
| 4916- | DSF, | Cu, | The immunomodulatory function and antitumor effect of disulfiram: paving the way for novel cancer therapeutics |
| - | Review, | Var, | NA |
| 4917- | DSF, | Chemo, | Cu, | Effect of Disulfiram and Copper Plus Chemotherapy vs Chemotherapy Alone on Survival in Patients With Recurrent Glioblastoma |
| - | Trial, | GBM, | NA |
| 4915- | DSF, | Cu, | Disulfiram: A novel repurposed drug for cancer therapy |
| - | Review, | Var, | NA |
| 5007- | DSF, | Cu, | Nrf2/HO-1 Alleviates Disulfiram/Copper-Induced Ferroptosis in Oral Squamous Cell Carcinoma |
| - | vitro+vivo, | Oral, | NA |
| 5008- | DSF, | Cu, | Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis |
| - | in-vitro, | HCC, | NA |
| - | vitro+vivo, | lymphoma, | NA |
| 5010- | DSF, | Cu, | Rad, | Disulfiram/Copper Combined with Irradiation Induces Immunogenic Cell Death in Melanoma |
| - | in-vivo, | Melanoma, | B16-F10 |
| 5011- | DSF, | Cu, | Leveraging disulfiram to treat cancer: Mechanisms of action, delivery strategies, and treatment regimens |
| - | Review, | Var, | NA |
| 5012- | DSF, | Cu, | Advancing Cancer Therapy with Copper/Disulfiram Nanomedicines and Drug Delivery Systems |
| - | Review, | Var, | NA |
| 5006- | DSF, | Cu, | Disulfiram targeting lymphoid malignant cell lines via ROS-JNK activation as well as Nrf2 and NF-kB pathway inhibition |
| - | vitro+vivo, | lymphoma, | NA |
| - | vitro+vivo, | Melanoma, | NA | - | Case Report, | Melanoma, | NA |
| 4255- | EA, | Effects of nutritional interventions on BDNF concentrations in humans: a systematic review |
| - | Review, | AD, | NA |
| 4254- | EA, | Chronic administration of ellagic acid improved the cognition in middle-aged overweight men |
| - | Human, | Obesity, | NA |
| - | Human, | MS, | NA | - | NA, | IBD, | NA |
| 4252- | EA, | Effect of ellagic acid on BDNF/PI3K/AKT-mediated signaling pathways in mouse models of depression |
| - | in-vivo, | AD, | NA |
| 4341- | EA, | Novel Bioactivity of Ellagic Acid in Inhibiting Human Platelet Activation |
| - | in-vitro, | Nor, | NA |
| 4832- | EA, | Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid |
| - | Review, | Var, | NA |
| 1607- | EA, | Exploring the Potential of Ellagic Acid in Gastrointestinal Cancer Prevention: Recent Advances and Future Directions |
| - | Review, | GC, | NA |
| 1605- | EA, | Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence |
| - | Review, | Var, | NA |
| 1621- | EA, | The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art |
| - | Review, | Var, | NA |
| 1620- | EA, | Rad, | Radiosensitizing effect of ellagic acid on growth of Hepatocellular carcinoma cells: an in vitro study |
| - | in-vitro, | Liver, | HepG2 |
| 1619- | EA, | CUR, | Antimutagenic Effect of the Ellagic Acid and Curcumin Combinations |
| - | in-vitro, | Nor, | NA |
| 1617- | EA, | CUR, | The inhibition of human glutathione S-transferases activity by plant polyphenolic compounds ellagic acid and curcumin |
| - | in-vitro, | Nor, | NA |
| 1606- | EA, | Ellagic acid inhibits proliferation and induced apoptosis via the Akt signaling pathway in HCT-15 colon adenocarcinoma cells |
| - | in-vitro, | Colon, | HCT15 |
| 1608- | EA, | Ellagic Acid from Hull Blackberries: Extraction, Purification, and Potential Anticancer Activity |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HUVECs |
| 1610- | EA, | Anticancer Effect of Pomegranate Peel Polyphenols against Cervical Cancer |
| - | Review, | Cerv, | NA |
| 1611- | EA, | Targeting Myeloperoxidase Activity and Neutrophil ROS Production to Modulate Redox Process: Effect of Ellagic Acid and Analogues |
| - | in-vitro, | Mal, | NA |
| 1612- | EA, | Negative Effect of Ellagic Acid on Cytosolic pH Regulation and Glycolytic Flux in Human Endometrial Cancer Cell |
| - | in-vitro, | EC, | NA |
| 1613- | EA, | Ellagitannins in Cancer Chemoprevention and Therapy |
| - | Review, | Var, | NA |
| 1614- | EA, | Bioavailability of ellagic acid in human plasma after consumption of ellagitannins from pomegranate (Punica granatum L.) juice |
| - | Human, | Nor, | NA |
| 1615- | EA, | Absorption, metabolism, and antioxidant effects of pomegranate (Punica granatum l.) polyphenols after ingestion of a standardized extract in healthy human volunteers |
| - | Human, | Nor, | NA |
| 1618- | EA, | A comprehensive review on Ellagic acid in breast cancer treatment: From cellular effects to molecular mechanisms of action |
| - | Review, | BC, | NA |
| 2402- | EA, | Ellagic Acid and Its Metabolites as Potent and Selective Allosteric Inhibitors of Liver Pyruvate Kinase |
| - | in-vitro, | Nor, | NA |
| 1110- | EA, | GEM, | Ellagic Acid Resensitizes Gemcitabine-Resistant Bladder Cancer Cells by Inhibiting Epithelial-Mesenchymal Transition and Gemcitabine Transporters |
| - | vitro+vivo, | Bladder, | NA |
| 1037- | EA, | Unripe Black Raspberry (Rubus coreanus Miquel) Extract and Its Constitute, Ellagic Acid Induces T Cell Activation and Antitumor Immunity by Blocking PD-1/PD-L1 Interaction |
| - | in-vivo, | CRC, | NA |
| 27- | EA, | Ellagic acid inhibits human pancreatic cancer growth in Balb c nude mice |
| - | in-vivo, | PC, | PANC1 |
| 6806- | EA, | Improving Effect of Ellagic Acid on Sleep Quality and Gastrointestinal Symptoms in Patient With Irritable Bowel Syndrome: Randomized Double-Blind Clinical Trial |
| - | Human, | IBD, | NA |
| 6805- | EA, | The gut microbiota urolithin metabotypes revisited: the human metabolism of ellagic acid is mainly determined by aging |
| - | Human, | Nor, | NA |
| 6804- | EA, | Ellagic acid metabolism by human gut microbiota: consistent observation of three urolithin phenotypes in intervention trials, independent of food source, age, and health status |
| - | Human, | Nor, | NA |
| 6803- | EA, | Effects of Ellagic Acid on Oxidative Stress Index, Inflammatory Markers and Quality of Life in Patients With Irritable Bowel Syndrome: Randomized Double-blind Clinical Trial |
| - | Trial, | IBD, | NA |
| 6802- | EA, | Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate |
| - | Human, | Pca, | NA |
| 6801- | EA, | A radiotherapeutic paradox: ellagic acid sensitizes tumors while attenuating radiation-induced myocardial injury |
| - | vitro+vivo, | BC, | 4T1 |
| 3756- | EA, | Acetylcholinesterase and monoamine oxidase-B inhibitory activities by ellagic acid derivatives isolated from Castanopsis cuspidata var. sieboldii |
| - | Analysis, | AD, | NA |
| 6769- | Ech, | Echinacea |
| - | Review, | Nor, | NA |
| 6616- | Ech, | Natural killer cells from aging mice treated with extracts from Echinacea purpurea are quantitatively and functionally rejuvenated |
| - | in-vivo, | Nor, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid